Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 39Lung Neoplasms 38Squamous Cell Carcinoma of Head and Neck 23Uterine Cervical Neoplasms 18Head and Neck Neoplasms 17Unspecified Adult Solid Tumor, Protocol Specific 13Central Nervous System Neoplasms 13Stomach Neoplasms 12Mesothelioma, Malignant 12Neuroblastoma 11Oropharyngeal Neoplasms 10Lymphoma 10Esophageal Neoplasms 10Ovarian Neoplasms 9Carcinoma, Ovarian Epithelial 9Urinary Bladder Neoplasms 8Adenocarcinoma of Lung 8Testicular Neoplasms 7Mouth Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Laryngeal Neoplasms 7Testicular Germ Cell Tumor 6Lymphoma, Large-Cell, Immunoblastic 6Carcinoma 6Astrocytoma 6Teratoma 5Small Cell Lung Carcinoma 5Peritoneal Neoplasms 5Oligodendroglioma 5

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Sinonasal Squamous Cell Carcinoma × Cisplatin × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡